We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
-15.02%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$271M
AUM Growth
-$50.6M
Cap. Flow
+$19.4M
Cap. Flow %
7.13%
Top 10 Hldgs %
90.62%
Holding
24
New
2
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$11.4M
2
NBTX
Nanobiotix
NBTX
+$7.96M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
1
Legend Biotech
LEGN
$3.93B
$54.7M 20.16%
814,586
– –
CVRX icon
2
CVRx
CVRX
$78.3M
$53M 19.53%
3,495,575
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$9.8B
$40.9M 15.05%
2,449,183
– –
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.17B
$32.6M 12.01%
6,641,064
– –
XNCR icon
5
Xencor
XNCR
$1.71B
$15.1M 5.55%
748,062
– –
NMRA icon
6
Neumora Therapeutics
NMRA
$321M
$12.9M 4.74%
+912,128
New +$11.4M
PRCT icon
7
Procept Biorobotics
PRCT
$1.26B
$11.7M 4.33%
357,939
– –
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$9.54M 3.52%
3,670,516
– –
NBTX
9
Nanobiotix
NBTX
$1.94B
$8.4M 3.09%
+959,637
New +$7.96M
FATE icon
10
Fate Therapeutics
FATE
$294M
$7.16M 2.64%
3,379,064
– –
PNT
11
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.67M 2.46%
1,000,000
– –
ARWR icon
12
Arrowhead Research
ARWR
$12.1B
$6.65M 2.45%
247,598
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$86.9M
$2.64M 0.97%
394,834
– –
HLTH
14
DELISTED
Cue Health Inc. Common Stock
HLTH
$2.45M 0.9%
5,548,864
– –
VOR icon
15
Vor Biopharma
VOR
$1.38B
$2.28M 0.84%
53,733
– –
NNOX icon
16
Nano X Imaging
NNOX
$73.2M
$2.08M 0.77%
317,704
– –
ACET icon
17
Adicet Bio
ACET
$77.3M
$999K 0.37%
45,559
– –
PHGE icon
18
BiomX
PHGE
$1.67M
$751K 0.28%
11,228
– –
SLGC
19
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$672K 0.25%
281,052
– –
CLSD
20
DELISTED
Clearside Biomedical
CLSD
$148K 0.05%
11,309
– –
APLM icon
21
Apollomics
APLM
$38.1M
$49.6K 0.02%
133
– –
SENS icon
22
Senseonics Holdings Inc
SENS
$409M
$33K 0.01%
2,731
– –
GYRE icon
23
Gyre Therapeutics
GYRE
$693M
$32.3K 0.01%
4,463
– –
TCON
24
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$15K 0.01%
4,200
– –

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q3 2023 Portfolio in Review

As of Q3 2023, Johnson & Johnson held 24 positions worth $271M, down 16% from $322M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Johnson & Johnson deployed $19.4M of net new capital in Q3 2023, opening 2 new positions. Its largest new stake was Neumora Therapeutics: 912,128 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's largest Q3 2023 buy was Neumora Therapeutics: 912,128 shares worth $12.9M.
  • Johnson & Johnson's ten largest holdings make up 91% of its $271M portfolio in Q3 2023.
  • Johnson & Johnson opened 2 new positions and closed 0 in Q3 2023.
  • Johnson & Johnson's portfolio value fell 16% quarter-over-quarter to $271M.

Based on Johnson & Johnson's 13F filing for Q3 2023, filed 9 Nov 2023.